Refile: Siga's mpox drug did not improve lesion resolution or pain, NIH study finds
10/12/2024 20:32
(Refiles to add media packaging code, with no changes to text)
Dec 10 (Reuters) - Siga Technologies' SIGA.O antiviral
drug tecovirimat did not reduce the time to lesion resolution or
have an effect on pain among adults affected by the clade II
strain of mpox, according to a National Institutes of Health
study published on Tuesday.
(Reporting by Sriparna Roy in Bengaluru; Editing by Pooja
Desai)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on SIGA Technologies
See all newsBrief: Siga Secures Contract Valued At Up To $15 Million From Canadian Department Of National Defence To Purchase Tpoxx®
SIGA Technologies Q2 revenue, profit drop as contract ends
SIGA Technologies Q1 revenue falls, net loss widens
Brief: SIGA Technologies Q1 EPS USD -0.05
Brief: EMA Recommends Restricting Use Of Tecovirimat SIGA